DHHS → node
Delivery System Reform Unit (DSRU) Provider Relations staff previously assigned by county are now assigned by policy. Please see the updated DRSU Provider Relations Staff contact information for the respective policies below.
Angelica Booker:
The Food and Drug Administration (FDA) announced on January 26, 2023, that Evusheld no longer has EAU.
Please see the impacted codes and detail below.
|
Astrazeneca EUA Pre-Exposure Prophylaxis Treatment-Evusheld |
||
|
Code |
Section 60, Medical Supplies and Durable Medical Equipment (DME): Summary of Rate Forum Comments and Department ResponsesIn September of 2022, the Office of MaineCare Services provided public notice that it initiated a rate determination for Section 60 Medical Supplies and DME prior to P.L. 2021 Ch. 639. Maine DHHS Temporarily Closes Lewiston Office Due to Damage From Cold WeatherAUGUSTA — The Maine Department of Health and Human Services (DHHS) closed its district office at 200 Main Street in Lewiston today due to water and electrical damage resulting from the extreme cold weather in the past few days. The office is undergoing repairs and will reopen to the public and employees as soon as possible to ensure continued access to critical benefits and services. Attention Providers of Sections 17, 28, and 65: Behavioral Health Rate FAQsAs mentioned in the notice on February 2, 2023, the Department now has available the Behavioral Health Rate FAQ document on billing and authorizations for serv Attention Providers of Section 31 Federally Qualified Health Centers (FQHC): Rebasing Stakeholder Informational Session: Presented MaterialsAs previously shared in our September 27, 2022 bulletin, the Department initiated a rate determination process for Section 31, Federally Qualified Health Centers, (FQHCs). Limited Availability of MaineCare Preferred Albuterol ProductsEffective January 20, 2023, MaineCare added additional albuterol products with preferred status to our Preferred Drug List (PDL). These preferred products do not require prior authorization (PA): XDEA License Requirement for Buprenorphine Claims RemovedOn December 29, 2022, Congress eliminated the “DATA-Waiver Program” with the signing of the Consolidated Appropriations Act of 2023 (the Act), improving access to buprenorphine for those in need. XDEA License Requirement for Buprenorphine Claims RemovedOn December 29, 2022, Congress eliminated the “DATA-Waiver Program” with the signing of the Consolidated Appropriations Act of 2023 (the Act), improving access to buprenorphine for those in need. XDEA License Requirement for Buprenorphine Claims RemovedOn December 29, 2022, Congress eliminated the “DATA-Waiver Program” with the signing of the Consolidated Appropriations Act of 2023 (the Act), improving access to buprenorphine for those in need. | |